Related Experiment Video
Updated: Jan 30, 2026
05:17
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
408
Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for
Yuwei Li1, Kaiyan Chen2, Hui Li2
1Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China; Postgraduate training base Alliance of Wenzhou Medical University, Hangzhou, Zhejiang 310022, China.
Cancer Treatment Reviews
|January 28, 2026
Summary
Antibody-drug conjugates (ADCs) show promise for treating extensive-stage small cell lung cancer (ES-SCLC). These targeted therapies offer improved efficacy against resistant tumors, with ongoing clinical trials exploring their potential.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with poor prognosis.
- Current treatments like immunochemotherapy have limitations, including disease recurrence and drug resistance.
- Antibody-drug conjugates (ADCs) represent a novel therapeutic strategy for SCLC.
Purpose of the Study:
- To systematically review ADCs in clinical trials and preclinical research for SCLC.
- To discuss the pharmacodynamics, efficacy, and adverse effects of these ADCs.
- To explore strategies for optimizing ADC treatment in SCLC.
Main Methods:
- Literature review of ADCs targeting antigens like B7-H3, Trop-2, SEZ6, DLL3, and EGFR-HER3 in SCLC.
- Analysis of data from clinical trials and preclinical studies.
- Comprehensive discussion of ADC characteristics and treatment optimization.
Main Results:
- Several ADCs targeting specific antigens have entered clinical trials for extensive-stage SCLC (ES-SCLC).
- Observed objective response rates (ORRs) range from 33.3% to 68.0%, with median progression-free survival (PFS) of 4.0-7.6 months.
- While some ADCs face toxicity challenges, many demonstrate encouraging efficacy.
Conclusions:
- ADCs targeting validated antigens are a promising therapeutic avenue for SCLC.
- Further research and clinical trials are essential to overcome toxicity and optimize treatment strategies.
- ADCs hold potential to improve outcomes for patients with SCLC, particularly those with resistant disease.
Related Concept Videos
02:50Conjugated Proteins
28.6K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
28.6K
02:57Targeted Cancer Therapies
8.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.9K
01:26Targets for Drug Action: Overview
10.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.2K
01:27Psychodynamic Perspectives on Personality
1.6K
The psychodynamic perspective in psychology asserts that most personality functions operate unconsciously, outside of awareness. This means that the motives and emotions driving behavior often remain hidden, automatically buried in the unconscious mind as a defense mechanism to shield us from psychological distress. According to this theory, the unconscious mind contains thoughts, memories, and emotions that are too disturbing to face directly.
Psychodynamic theorists argue that unconscious...
Psychodynamic theorists argue that unconscious...
1.6K
01:19Conjugation
2.3K
Conjugation is a form of horizontal gene transfer that primarily occurs in bacteria and some archaea, promoting genetic diversity and adaptation. Bacteria can acquire resistance genes through conjugative plasmids, allowing them to survive antibiotic treatments that would otherwise be lethal. This process involves direct contact between cells through specialized structures such as the sex pilus and is mediated by conjugative plasmids, including the F (fertility) factor.Conjugation requires...
2.3K
01:47Lung Capacity
56.3K
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.3K